Business Wire

MO-BLUE-YONDER

Share
Nestlé Purina Petcare Takes Category Management Strategy Into the Metaverse With Blue Yonder and 3DVR Solutions

To improve customer experience and satisfaction, retailers are looking to offer a personalized assortment and easy to navigate display of products in their stores. That’s why Nestlé Purina Petcare, the leading manufacturer of pet care products, has successfully implemented Blue Yonder’s category management solution integrated with 3DVR Solutions’ (3DVRS) 3D virtual reality technology to assist its retail partners with better merchandizing of their store shelfs.

Purina is the No. 1 pet care company in the U.S. It offers more than 20 brands in the U.S., feeding 65 million dogs and 51 million cats annually. Purina provides its retail partners with planograms that design shelfs aimed at merchandizing products to meet customer needs. However, with travel restricted during the COVID-19 lockdowns, it needed an alternate way for its associates to work with its retail partners remotely to replicate critical tasks that would otherwise be performed in front of a physical planogram or in store.

Enter 3DVRS’ innovative Retail Visualisation Suite (RVS) Virtual Reality (VR) Headset solution, which combines planogram data from Blue Yonder with a cutting-edge virtual reality headset provider to deliver a fully interactive, networked avatar-based merchandising solution. This integrated solution brings people from all over the globe into a common unique headset experience in the metaverse where they can plan, present and interact. The integrated solution is now also available to other companies who are looking to solve similar challenges.

Thanks to this integrated solution, Purina has achieved some key benefits:

  • Removed the need to be in a physical store to make shelfing decisions by bringing people together in the metaverse, which has in turn reduced environmental impact from less travel and decreased training costs.
  • Reduced time to merchandise a shelf via an interactive planogram before moving real product.
  • Incorporated true-to-life factors into shelf planning.
  • Partner with retailers to enhance the customer journey in store and share global best practices.

“3DVRS’ integration with Blue Yonder delivers flexibility, speed and scale, giving us the ability to effectively deploy across the business. The evolution from virtual reality on the desktop to network avatars in the RVS VR Headset solution has been seamless. We can now hold meetings virtually in the metaverse, interact with layouts, products, and store innovations, allowing us to be right at the cutting edge,” said Gene Feldman, training manager, Purina.

Together, Blue Yonder's category management and 3DVRS’ RVS VR Headset solutions have enabled Purina’s retail partners to make faster, more accurate and localized space allocation decisions to help their customers find the products they need more easily while guaranteeing a better shopping and service experience.

“Purina is a fantastic partner to innovate with as they are always looking to the latest technology to give their business the edge. The challenges they presented pushed technological boundaries. Our integration with Blue Yonder gives us the platform to support large enterprises such as Purina. It’s great to bring new tech to the market that makes a real difference. It’s amazing what we have achieved together already, but I sense there's a lot more to come,” said Nigel Hemer, CEO and founder, 3DVR Solutions.

“Working with 3DVRS has allowed us to bring Blue Yonder’s planograms to life in the metaverse where users can merchandise, analyze, interact, and meet as avatars to design shelfs that meet customers’ needs. This is cutting-edge technology at its finest and Purina was one of the first companies to benefit from it. By creating a culture of innovation and thought leadership throughout the organization, Purina is building a great place to work for both their associates and retail partners,” said Phillip Teschemacher, corporate vice president, Manufacturing - EMEA, Blue Yonder.

Additional Resources:

About Nestlé Purina PetCare

Nestlé Purina PetCare creates richer lives for pets and the people who love them. Founded in 1894, Purina has helped dogs and cats live longer, healthier lives by offering scientifically based nutritional innovations.

Purina manufactures some of the world's most trusted and popular pet care products, including Purina Cat Chow, Purina ONE, Pro Plan, Fancy Feast and Tidy Cats. Our more than 8,700 U.S. associates take pride in our trusted pet food, treat and litter brands that feed 51 million dogs and 65 million cats every year. More than 500 Purina scientists, veterinarians, and pet care experts ensure our commitment to unsurpassed quality and nutrition. Purina promotes responsible pet care through our scientific research, our products and our support for pet-related organizations.

Over the past five years, Purina has contributed more than $150 million towards organizations that bring, and keep, people and pets together, as well as those that help our communities and environment thrive. Purina is part of Nestlé, a global leader in Nutrition, Health and Wellness. For more information, visit purina.com or subscribe here to get the latest Purina news.

About 3DVR Solutions

As a global Blue Yonder technology partner for 10 years, 3DVRS leverages Blue Yonder planogram and store CAD data to create highly visual 3D environments, enabling retailers & suppliers to plan, design and respond to rapidly changing market conditions. The unique design of 3DVR’s virtual reality solutions deliver automation, speed and scale without inherent dependencies and costs. 3DVR support Blue Yonder customers around the globe, including those on Microsoft Azure. www.3dvrs.com

About Blue Yonder

Blue Yonder is the world leader in digital supply chain transformations and omni-channel commerce fulfillment. Our end-to-end, cognitive business platform enables retailers, manufacturers and logistics providers to best fulfill customer demand from planning through delivery. With Blue Yonder, you'll unify your data, supply chain and retail commerce operations to unlock new business opportunities and drive automation, control and orchestration to enable more profitable, sustainable business decisions. Blue Yonder - Fulfill your Potential blueyonder.com

“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005378/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye